Fredun Pharmaceuticals Announces Un-Audited Financial Results for Quarter Ended June 30, 2026
Fredun Pharmaceuticals Ltd has released its un-audited financial results for the quarter ended June 30, 2026. The results include a comparative look at various key financial metrics across different reporting periods.The company's financial performance is detailed across multiple metrics and timeframes, with data provided as follows:
| Financial Metric | Q1 FY26 (Quarter Ended 30.06.2026) | Q1 FY25 (Quarter Ended 30.06.2025) | Q1 FY26 (Ended 31.03.2026) |
|---|---|---|---|
| Operating Income (Total) | 4802.4 | 2001.4 | 5612.6 |
| Sales Revenue (Wholesale/Retail) | 4802.4 | 3602.9 | 5612.6 |
| Net Profit (Wholesale/Retail) | 3602.9 | 1374.0 | 4201.0 |
| EBITDA Margin | 3662.8 | 1312.9 | 4104.2 |
| Average Net Profit | 432.9 | 432.9 | 432.9 |
| Shareholder Equity Earnings (A/c based) | - | - | 39141.7 |
| Affiliate Income | 80.4 | 33.9 | 96.2 |
| Consolidated Profit | 2.9 | (2.2) | 0.9 |
| Net Operating Margin | 83.3 | 31.7 | 97.1 |
The company reported several other operational metrics:
- Revenue: The total revenue for the quarter ending June 30, 2026 was reported at 48374.4, compared to 37517.8 in the corresponding period of FY25 and 149854.0 in the specified comparative period.
- Wholesale Revenue: The revenue for wholesale trade during Q1 FY26 was reported at 4811.1, against 2005.5 in the comparable previous year and 5619.9 in the third-quarter comparison period.
These figures provide insight into the company's performance across various operational metrics relevant to its pharmaceutical business.
Stock Price Movement
Fredun Pharmaceuticals Ltd settled at ₹1221.80 on Thursday after dropping 6.97%.The shares traded within an intraday range of ₹1201.00 to ₹1331.00 during the session.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.